Skip to main content
Retour
LEGN logo

Legend Biotech Corporation

Qualité des données : 100%
LEGN
NASDAQ Healthcare Biotechnology
17,60 €
▲ 0,51 € (2,98%)
Cap. Boursière : 3,26B
Fourchette du Jour
17,26 € 17,82 €
Fourchette 52 Semaines
16,24 € 45,30 €
Volume
1 102 321
Moyenne 50J / 200J
19,12 € / 29,31 €
Clôture Précédente
17,09 €

Quick Summary

Historique des Prix

Tendances Financières

Comparaison Sectorielle

vs médiane du secteur Healthcare (631 pairs)

Métrique Action Médiane du Secteur
P/E -10,9 0,2
P/B 3,3 3,0
ROE % -29,1 3,6
Net Margin % -28,9 3,8
Rev Growth 5Y % 96,8 9,9
D/E 0,4 0,2

Objectif de Cours des Analystes

Hold
58,60 € +233.0%
Low: 24,00 € High: 75,00 €
P/E Prévisionnel
71,64
BPA Prévisionnel
0,24 €
Croissance BPA (est.)
+0,0%
CA Est.
1,44B

Estimations de Bénéfices

Période BPA Est. CA Est. Analystes
FY2030 2,13 €
1,80 € – 2,44 €
2,77B 1
FY2029 1,95 €
1,64 € – 2,23 €
2,53B 1
FY2028 1,72 €
1,45 € – 1,97 €
2,12B 1

Earnings Surprises

Last 8 quarters
Quarter Est. EPS Actual EPS Surprise
2026-03-10 0,00 € -0,08 € -15194,3%
2025-11-12 -0,13 € -0,11 € +15,4%
2025-08-11 -0,22 € -0,34 € -54,5%
2025-05-13 -0,40 € -0,07 € +82,5%
2025-03-11 -0,39 € -0,15 € +61,5%
2024-08-09 -0,54 € -0,05 € +90,7%
2024-05-13 -0,29 € -0,16 € +44,8%
2024-03-11 -0,70 € -0,40 € +42,9%

Dividend History

Yield

0,00%

Payout Ratio

0,00%

Growth (3Y)

N/A

Growth (5Y)

N/A

No dividend history available.

Points Clés

Revenue grew 96,76% annually over 5 years — strong growth
Debt/Equity of 0,41 — conservative balance sheet
Negative free cash flow of -168,04M
Revenue growth is decelerating — 1Y growth trails 5Y average by 32,29%
Capital efficient — spends only 6,55% of revenue on capex

Croissance

Revenue Growth (5Y)
96,76%
Revenue (1Y)64,47%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Qualité

Return on Equity
-29,14%
ROIC-7,25%
Net Margin-28,85%
Op. Margin-13,27%

Sécurité

Debt / Equity
0,41
Current Ratio1,96
Interest Coverage-6,38

Valorisation

P/E Ratio
-10,94
Forward P/E71,64
P/B Ratio3,25
EV/EBITDAN/A
Dividend Yield0,00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 64,47% Revenue Growth (3Y) 90,21%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) 96,76% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 1,03B Net Income (TTM) -297,58M
ROE -29,14% ROA -17,16%
Gross Margin 60,34% Operating Margin -13,27%
Net Margin -28,85% Free Cash Flow (TTM) -168,04M
ROIC -7,25% FCF Growth (3Y) N/A
Safety
Debt / Equity 0,41 Current Ratio 1,96
Interest Coverage -6,38
Dividends
Dividend Yield 0,00% Payout Ratio 0,00%
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -10,94 Forward P/E 71,64
P/B Ratio 3,25 P/S Ratio 3,16
PEG Ratio -0,21 Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S 2,27 Fwd Earnings Yield 1,40%
FCF Yield -5,16%
Market Cap 3,26B Enterprise Value 2,77B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 1,03B 627,24M 285,14M 117,01M 68,83M
Net Income -297,58M -177,03M -518,25M -446,35M -403,58M
EPS (Diluted) -1,60 -0,97 -2,94 -2,81 -2,74
Gross Profit 622,44M 392,66M 140,93M 51,64M 68,83M
Operating Income -136,86M -303,24M -439,49M -455,62M -392,29M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 1,73B 1,67B 1,85B 1,33B 1,12B
Total Liabilities 723,60M 629,61M 597,24M 586,65M 353,52M
Shareholders' Equity 1,00B 1,04B 1,25B 744,31M 765,94M
Total Debt 413,70M 350,60M 328,67M 284,53M 122,97M
Cash & Equivalents 901,90M 286,75M 1,28B 786,03M 688,94M
Current Assets 1,25B 1,28B 1,50B 1,10B 949,85M
Current Liabilities 636,40M 277,65M 216,42M 297,79M 229,20M